aTyr Pharma (NASDAQ:ATYR) Given New $4.00 Price Target at Wells Fargo & Company

aTyr Pharma (NASDAQ:ATYR) had its price objective increased by research analysts at Wells Fargo & Company from $1.00 to $4.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective points to a potential downside of 34.36% from the stock’s current price.

ATYR has been the subject of a number of other reports. Weiss Ratings cut aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Wall Street Zen raised shares of aTyr Pharma to a “hold” rating in a report on Saturday, October 31st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.

aTyr Pharma Price Performance

ATYR stock opened at $6.09 on Friday. The business has a fifty day moving average price of $11.99 and a 200 day moving average price of $23.70. aTyr Pharma has a fifty-two week low of $4.07 and a fifty-two week high of $44.40. The stock has a market capitalization of $14.94 million, a price-to-earnings ratio of -0.25 and a beta of 1.04.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings data on Friday, November 6th. The company reported ($7.43) EPS for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43). On average, equities analysts expect that aTyr Pharma will post -17.80 earnings per share for the current fiscal year.

Hedge Funds Weigh In On aTyr Pharma

An institutional investor recently bought a new stake in aTyr Pharma stock. Renaissance Technologies LLC purchased a new stake in aTyr Pharma, Inc. (NASDAQ:ATYR) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 40,522 shares of the company’s stock, valued at approximately $32,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.